ClinicalTrials.gg
CompletedNCT05587478Updated Sep 1, 2023

A Study of EDP-323 in Healthy Subjects

A Phase 1 interventional study of EDP-323 and Placebo in RSV Infection, sponsored by Enanta Pharmaceuticals, Inc. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-01.

Sponsored by Enanta Pharmaceuticals, Inc · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2023, 3 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
82
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies in Respiratory Syncytial Virus Infections by Enanta Pharmaceuticals, Inc — 1 open to participants now, 1 under way, none of them phase 3. Respiratory Syncytial Virus Infections · Enanta Pharmaceuticals, Inc.

Enrollment
7th of 14
82 · median 77
Started
2022
with 1 other
Phase 1
9 of 14
none open now
Registered
9th of 14
by date

Among the 14 studies in Respiratory Syncytial Virus Infections by Enanta Pharmaceuticals, Inc, this one is the 7th largest by enrollment, is one of 2 that started in 2022, is one of 9 in phase 1, and was the 9th registered.

Respiratory Syncytial Virus Infections

306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

1 of the 14 studies in Respiratory Syncytial Virus Infections by Enanta Pharmaceuticals, Inc is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Respiratory Syncytial Virus Infections by Enanta Pharmaceuticals, Inc, or all of them as a file.
02

Study summary

This study is a randomized, double-blind, sponsor-open, placebo-controlled study. It will assess the safety, tolerability, and pharmacokinetics of orally administered single and multiple doses of EDP-323 in healthy adult subjects.

03

Conditions studied

  • RSV Infection

Keywords

  • First-in-Human
  • Single Ascending Dose
  • Multiple Ascending Dose
  • Healthy Volunteer
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • An document signed and dated by the subject.
  • Healthy male and female subjects of any ethnic origin between the ages of 18 and 65 years, inclusive.

Exclusion criteria

Exclusion Criteria:

  • evidence or history of illness or disease.
  • Infection with (HIV), virus (HBV), or virus (HCV) at screening and infection with SARS-CoV-2 at the Day -1 visit
  • Pregnant or nursing females.
  • History of febrile illness within 7 days prior to the first dose of study drug or subjects with evidence of active infection.
  • A positive urine drug screen at screening or Day -1.
  • Current tobacco smokers or use of tobacco within 3 months prior to screening.
  • Any condition possibly affecting drug absorption (e.g., gastrectomy, cholecystectomy).
  • History of regular alcohol consumption.
  • Receipt of any vaccine, an agent or biological product within 28 days or 5 times the t½, whichever one is longer, prior to first dose.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
82 participants (actual)

Study arms

  • Experimental
    EDP-323 SAD Cohorts

    EDP-323 Dose 1, Dose 2, Dose 3, Dose 4, Dose 5 and Dose 6, orally, once daily in one single administration

    Drug: EDP-323

  • Experimental
    EDP-323 MAD Cohorts

    EDP-323 Dose 1, Dose 2, Dose 3 and Dose 4 orally, once daily for 7 days

    Drug: EDP-323

  • Placebo comparator
    EDP-323 SAD Placebo Cohorts

    Matching placebo, orally, once daily in one single administration

    Drug: Placebo

  • Placebo comparator
    EDP-323 MAD Placebo Cohorts

    Matching placebo, orally, once daily for 7 days

    Drug: Placebo

Interventions

  • Oral administration

  • DrugPlacebo

    Placebo to match EDP-323, oral administration

06

What researchers measure

Primary outcomes

  1. Safety measured by adverse events

    Time frame: Up to 8 Days in SAD Cohorts

  2. Safety measured by adverse events

    Time frame: Up to 14 Days in MAD Cohorts

Secondary outcomes

  1. Cmax of EDP-323

    Time frame: Up to 5 Days in SAD Cohorts

  2. AUC of EDP-323

    Time frame: Up to 5 Days in SAD Cohorts

  3. Cmax of EDP-323

    Time frame: Up to 11 Days in MAD Cohorts

  4. AUC of EDP-323

    Time frame: Up to 11 Days in MAD Cohorts

07

Study locations

1 site
  • ICON, plc.
    Lenexa, Kansas 66219, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Mar 2023, 6 months.

Of 44 industry-sponsored phase 1 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 6 months is close to that.

Counting every sponsor, half of 57 studies reached it within 8 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2022
First posted
Oct 20, 2022
StartActual
Sep 29, 2022
Primary completionActual
Mar 29, 2023
CompletionActual
Mar 29, 2023
Last update
Sep 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05587478
Responsible party
Sponsor
First posted
Oct 20, 2022
Start date
Sep 29, 2022
Primary completion
Mar 29, 2023
Completion
Mar 29, 2023
Last update
Sep 1, 2023

Study contacts

Enanta Pharmaceuticals, Inc
study director · Enanta Pharmaceuticals, Inc

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: EDP-323

Start the discussion